Global Immunoprotein Diagnostic Testing Market

Immunoprotein Diagnostic Testing Comprehensive Study by Type (C-reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Pre-albumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, Free Light Chain Diagnostic Test, Others), Application (Disease Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, Toxicology Testing, Other), Technology (Radioimmunoassay, Immunoturbidity Assay, Immunoprotein Electrophoresis, Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay), Others), End User (Laboratories, Hospitals, Diagnostic Centers and Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2030

Immunoprotein Diagnostic Testing Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 20.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Immunoprotein Diagnostic Testing Market Overview:
Immunoprotein diagnostic testing market is expected to gain market growth in the forecast period due to a surging volume of patients suffering from chronic as well as infectious diseases and increasing demand for early diagnostic services. Immunoprotein diagnostic testing detects the level of proteins in the body, and thereby, it helps in the diagnosis of diseases. An increasing number of infectious diseases and lifestyle-induced health conditions has been the leading driver for the immunoprotein diagnostic testing market. As per latest study released by AMA Research, the Global Immunoprotein Diagnostic Testing market is expected to see growth rate of 20.3%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Technological Advancements in Immunodiagnostic Instruments Introduction of Novel Automated Systems

Market Growth Drivers:
Increase in Incidence & Prevalence of Infectious and Chronic Diseases and Rising Geriatric Population Coupled with a High Prevalence of Non- Communicable Diseases

Challenges:
Complex Regulatory Framework for the Approval of Various Immunoprotein Diagnostic Tests

Restraints:
High Cost of Diagnosis and Unaffordability of Low-Income Patients

Opportunities:
Surging Development in the Condition-Specific Assays & Tests and Increasing Need for Early Diagnosis in the Emerging Economies

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Abbott Laboratories (United States), Abcam PLC (United Kingdom), Bio-Rad Laboratories (United States), Danaher Corporation (United States), Diasorin (Italy), Roche Diagnostics (Switzerland), Beckman Coulter (United States), F. Hoffman-La Roche Ltd. (Switzerland) and Siemens Healthineers (Germany). Additionally, following companies can also be profiled that are part of our coverage like A. Menarini Diagnostics (Italy), Affymetrix (United States) and Agilent Technologies (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Immunoprotein Diagnostic Testing market by 2030. Considering Market by Technology, the sub-segment i.e. Radioimmunoassay will boost the Immunoprotein Diagnostic Testing market. Considering Market by End User, the sub-segment i.e. Laboratories will boost the Immunoprotein Diagnostic Testing market.

Latest Market Insights:
In June 2019, Eurobio scientific entered into an exclusive negotiation with Vivo medical group for the acquisition of Pathway Diagnostics Ltd and Personal Diagnostics Ltd, two British companies specializing respectively in the development and distribution of in vitro diagnostic tests in the U.K and Ireland, and self-tests for consumers and professionals via an e-commerce platform.

In April 2019, Meridian Bioscience Inc., a provider of diagnostics solutions and raw material, entered into a definitive agreement to acquire the business of GenoPic Inc., a provider of molecular diagnostic instruments and assays. With this acquisition, Meridian will be getting GenePOC’s state-of-the-art revenue molecular diagnostics platform, which offers samples to result in testing for single tests, as well as flexible multiplexing capability.

What Can be Explored with the Immunoprotein Diagnostic Testing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Immunoprotein Diagnostic Testing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Immunoprotein Diagnostic Testing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Immunoprotein Diagnostic Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Immunoprotein Diagnostic Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Immunoprotein Diagnostic Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • C-reactive Protein Diagnostic Test
  • Complement System Protein Diagnostic Test
  • Pre-albumin Diagnostic Test
  • Haptoglobin Diagnostic Test
  • Immunoglobulin Diagnostic Test
  • Free Light Chain Diagnostic Test
  • Others
By Application
  • Disease Testing
  • Infectious Disease Testing
  • Allergy Testing
  • Endocrine Testing
  • Oncology Testing
  • Toxicology Testing
  • Other
By Technology
  • Radioimmunoassay
  • Immunoturbidity Assay
  • Immunoprotein Electrophoresis
  • Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay)
  • Others

By End User
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Incidence & Prevalence of Infectious and Chronic Diseases
      • 3.2.2. Rising Geriatric Population Coupled with a High Prevalence of Non- Communicable Diseases
    • 3.3. Market Challenges
      • 3.3.1. Complex Regulatory Framework for the Approval of Various Immunoprotein Diagnostic Tests
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Immunodiagnostic Instruments Introduction of Novel Automated Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Immunoprotein Diagnostic Testing, by Type, Application, Technology, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Immunoprotein Diagnostic Testing (Value)
      • 5.2.1. Global Immunoprotein Diagnostic Testing by: Type (Value)
        • 5.2.1.1. C-reactive Protein Diagnostic Test
        • 5.2.1.2. Complement System Protein Diagnostic Test
        • 5.2.1.3. Pre-albumin Diagnostic Test
        • 5.2.1.4. Haptoglobin Diagnostic Test
        • 5.2.1.5. Immunoglobulin Diagnostic Test
        • 5.2.1.6. Free Light Chain Diagnostic Test
        • 5.2.1.7. Others
      • 5.2.2. Global Immunoprotein Diagnostic Testing by: Application (Value)
        • 5.2.2.1. Disease Testing
        • 5.2.2.2. Infectious Disease Testing
        • 5.2.2.3. Allergy Testing
        • 5.2.2.4. Endocrine Testing
        • 5.2.2.5. Oncology Testing
        • 5.2.2.6. Toxicology Testing
        • 5.2.2.7. Other
      • 5.2.3. Global Immunoprotein Diagnostic Testing by: Technology (Value)
        • 5.2.3.1. Radioimmunoassay
        • 5.2.3.2. Immunoturbidity Assay
        • 5.2.3.3. Immunoprotein Electrophoresis
        • 5.2.3.4. Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay)
        • 5.2.3.5. Others
      • 5.2.4. Global Immunoprotein Diagnostic Testing by: End User (Value)
        • 5.2.4.1. Laboratories
        • 5.2.4.2. Hospitals
        • 5.2.4.3. Diagnostic Centers and Clinics
        • 5.2.4.4. Research Institutes
        • 5.2.4.5. Others
      • 5.2.5. Global Immunoprotein Diagnostic Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Immunoprotein Diagnostic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abcam PLC (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bio-Rad Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Diasorin (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Roche Diagnostics (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Beckman Coulter (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens Healthineers (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Immunoprotein Diagnostic Testing Sale, by Type, Application, Technology, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Immunoprotein Diagnostic Testing (Value)
      • 7.2.1. Global Immunoprotein Diagnostic Testing by: Type (Value)
        • 7.2.1.1. C-reactive Protein Diagnostic Test
        • 7.2.1.2. Complement System Protein Diagnostic Test
        • 7.2.1.3. Pre-albumin Diagnostic Test
        • 7.2.1.4. Haptoglobin Diagnostic Test
        • 7.2.1.5. Immunoglobulin Diagnostic Test
        • 7.2.1.6. Free Light Chain Diagnostic Test
        • 7.2.1.7. Others
      • 7.2.2. Global Immunoprotein Diagnostic Testing by: Application (Value)
        • 7.2.2.1. Disease Testing
        • 7.2.2.2. Infectious Disease Testing
        • 7.2.2.3. Allergy Testing
        • 7.2.2.4. Endocrine Testing
        • 7.2.2.5. Oncology Testing
        • 7.2.2.6. Toxicology Testing
        • 7.2.2.7. Other
      • 7.2.3. Global Immunoprotein Diagnostic Testing by: Technology (Value)
        • 7.2.3.1. Radioimmunoassay
        • 7.2.3.2. Immunoturbidity Assay
        • 7.2.3.3. Immunoprotein Electrophoresis
        • 7.2.3.4. Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay)
        • 7.2.3.5. Others
      • 7.2.4. Global Immunoprotein Diagnostic Testing by: End User (Value)
        • 7.2.4.1. Laboratories
        • 7.2.4.2. Hospitals
        • 7.2.4.3. Diagnostic Centers and Clinics
        • 7.2.4.4. Research Institutes
        • 7.2.4.5. Others
      • 7.2.5. Global Immunoprotein Diagnostic Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Immunoprotein Diagnostic Testing: by Type(USD Million)
  • Table 2. Immunoprotein Diagnostic Testing C-reactive Protein Diagnostic Test , by Region USD Million (2018-2023)
  • Table 3. Immunoprotein Diagnostic Testing Complement System Protein Diagnostic Test , by Region USD Million (2018-2023)
  • Table 4. Immunoprotein Diagnostic Testing Pre-albumin Diagnostic Test , by Region USD Million (2018-2023)
  • Table 5. Immunoprotein Diagnostic Testing Haptoglobin Diagnostic Test , by Region USD Million (2018-2023)
  • Table 6. Immunoprotein Diagnostic Testing Immunoglobulin Diagnostic Test , by Region USD Million (2018-2023)
  • Table 7. Immunoprotein Diagnostic Testing Free Light Chain Diagnostic Test , by Region USD Million (2018-2023)
  • Table 8. Immunoprotein Diagnostic Testing Others , by Region USD Million (2018-2023)
  • Table 9. Immunoprotein Diagnostic Testing: by Application(USD Million)
  • Table 10. Immunoprotein Diagnostic Testing Disease Testing , by Region USD Million (2018-2023)
  • Table 11. Immunoprotein Diagnostic Testing Infectious Disease Testing , by Region USD Million (2018-2023)
  • Table 12. Immunoprotein Diagnostic Testing Allergy Testing , by Region USD Million (2018-2023)
  • Table 13. Immunoprotein Diagnostic Testing Endocrine Testing , by Region USD Million (2018-2023)
  • Table 14. Immunoprotein Diagnostic Testing Oncology Testing , by Region USD Million (2018-2023)
  • Table 15. Immunoprotein Diagnostic Testing Toxicology Testing , by Region USD Million (2018-2023)
  • Table 16. Immunoprotein Diagnostic Testing Other , by Region USD Million (2018-2023)
  • Table 17. Immunoprotein Diagnostic Testing: by Technology(USD Million)
  • Table 18. Immunoprotein Diagnostic Testing Radioimmunoassay , by Region USD Million (2018-2023)
  • Table 19. Immunoprotein Diagnostic Testing Immunoturbidity Assay , by Region USD Million (2018-2023)
  • Table 20. Immunoprotein Diagnostic Testing Immunoprotein Electrophoresis , by Region USD Million (2018-2023)
  • Table 21. Immunoprotein Diagnostic Testing Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay) , by Region USD Million (2018-2023)
  • Table 22. Immunoprotein Diagnostic Testing Others , by Region USD Million (2018-2023)
  • Table 23. Immunoprotein Diagnostic Testing: by End User(USD Million)
  • Table 24. Immunoprotein Diagnostic Testing Laboratories , by Region USD Million (2018-2023)
  • Table 25. Immunoprotein Diagnostic Testing Hospitals , by Region USD Million (2018-2023)
  • Table 26. Immunoprotein Diagnostic Testing Diagnostic Centers and Clinics , by Region USD Million (2018-2023)
  • Table 27. Immunoprotein Diagnostic Testing Research Institutes , by Region USD Million (2018-2023)
  • Table 28. Immunoprotein Diagnostic Testing Others , by Region USD Million (2018-2023)
  • Table 29. South America Immunoprotein Diagnostic Testing, by Country USD Million (2018-2023)
  • Table 30. South America Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 31. South America Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 32. South America Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 33. South America Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 34. Brazil Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 35. Brazil Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 36. Brazil Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 37. Brazil Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 38. Argentina Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 39. Argentina Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 40. Argentina Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 41. Argentina Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 42. Rest of South America Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 43. Rest of South America Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 44. Rest of South America Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 45. Rest of South America Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 46. Asia Pacific Immunoprotein Diagnostic Testing, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 48. Asia Pacific Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 49. Asia Pacific Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 50. Asia Pacific Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 51. China Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 52. China Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 53. China Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 54. China Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 55. Japan Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 56. Japan Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 57. Japan Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 58. Japan Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 59. India Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 60. India Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 61. India Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 62. India Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 63. South Korea Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 64. South Korea Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 65. South Korea Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 66. South Korea Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 67. Taiwan Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 68. Taiwan Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 69. Taiwan Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 70. Taiwan Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 71. Australia Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 72. Australia Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 73. Australia Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 74. Australia Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 79. Europe Immunoprotein Diagnostic Testing, by Country USD Million (2018-2023)
  • Table 80. Europe Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 81. Europe Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 82. Europe Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 83. Europe Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 84. Germany Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 85. Germany Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 86. Germany Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 87. Germany Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 88. France Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 89. France Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 90. France Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 91. France Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 92. Italy Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 93. Italy Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 94. Italy Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 95. Italy Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 96. United Kingdom Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 97. United Kingdom Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 98. United Kingdom Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 99. United Kingdom Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 100. Netherlands Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 101. Netherlands Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 102. Netherlands Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 103. Netherlands Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 104. Rest of Europe Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 105. Rest of Europe Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 106. Rest of Europe Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 107. Rest of Europe Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 108. MEA Immunoprotein Diagnostic Testing, by Country USD Million (2018-2023)
  • Table 109. MEA Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 110. MEA Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 111. MEA Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 112. MEA Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 113. Middle East Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 114. Middle East Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 115. Middle East Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 116. Middle East Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 117. Africa Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 118. Africa Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 119. Africa Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 120. Africa Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 121. North America Immunoprotein Diagnostic Testing, by Country USD Million (2018-2023)
  • Table 122. North America Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 123. North America Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 124. North America Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 125. North America Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 126. United States Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 127. United States Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 128. United States Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 129. United States Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 130. Canada Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 131. Canada Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 132. Canada Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 133. Canada Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 134. Mexico Immunoprotein Diagnostic Testing, by Type USD Million (2018-2023)
  • Table 135. Mexico Immunoprotein Diagnostic Testing, by Application USD Million (2018-2023)
  • Table 136. Mexico Immunoprotein Diagnostic Testing, by Technology USD Million (2018-2023)
  • Table 137. Mexico Immunoprotein Diagnostic Testing, by End User USD Million (2018-2023)
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Immunoprotein Diagnostic Testing: by Type(USD Million)
  • Table 148. Immunoprotein Diagnostic Testing C-reactive Protein Diagnostic Test , by Region USD Million (2025-2030)
  • Table 149. Immunoprotein Diagnostic Testing Complement System Protein Diagnostic Test , by Region USD Million (2025-2030)
  • Table 150. Immunoprotein Diagnostic Testing Pre-albumin Diagnostic Test , by Region USD Million (2025-2030)
  • Table 151. Immunoprotein Diagnostic Testing Haptoglobin Diagnostic Test , by Region USD Million (2025-2030)
  • Table 152. Immunoprotein Diagnostic Testing Immunoglobulin Diagnostic Test , by Region USD Million (2025-2030)
  • Table 153. Immunoprotein Diagnostic Testing Free Light Chain Diagnostic Test , by Region USD Million (2025-2030)
  • Table 154. Immunoprotein Diagnostic Testing Others , by Region USD Million (2025-2030)
  • Table 155. Immunoprotein Diagnostic Testing: by Application(USD Million)
  • Table 156. Immunoprotein Diagnostic Testing Disease Testing , by Region USD Million (2025-2030)
  • Table 157. Immunoprotein Diagnostic Testing Infectious Disease Testing , by Region USD Million (2025-2030)
  • Table 158. Immunoprotein Diagnostic Testing Allergy Testing , by Region USD Million (2025-2030)
  • Table 159. Immunoprotein Diagnostic Testing Endocrine Testing , by Region USD Million (2025-2030)
  • Table 160. Immunoprotein Diagnostic Testing Oncology Testing , by Region USD Million (2025-2030)
  • Table 161. Immunoprotein Diagnostic Testing Toxicology Testing , by Region USD Million (2025-2030)
  • Table 162. Immunoprotein Diagnostic Testing Other , by Region USD Million (2025-2030)
  • Table 163. Immunoprotein Diagnostic Testing: by Technology(USD Million)
  • Table 164. Immunoprotein Diagnostic Testing Radioimmunoassay , by Region USD Million (2025-2030)
  • Table 165. Immunoprotein Diagnostic Testing Immunoturbidity Assay , by Region USD Million (2025-2030)
  • Table 166. Immunoprotein Diagnostic Testing Immunoprotein Electrophoresis , by Region USD Million (2025-2030)
  • Table 167. Immunoprotein Diagnostic Testing Enzyme-linked Immunosorbent Assay (Chemiluminescence Immunoassay, Fluorescence Immunoassay, and Colorimetric Immunoassay) , by Region USD Million (2025-2030)
  • Table 168. Immunoprotein Diagnostic Testing Others , by Region USD Million (2025-2030)
  • Table 169. Immunoprotein Diagnostic Testing: by End User(USD Million)
  • Table 170. Immunoprotein Diagnostic Testing Laboratories , by Region USD Million (2025-2030)
  • Table 171. Immunoprotein Diagnostic Testing Hospitals , by Region USD Million (2025-2030)
  • Table 172. Immunoprotein Diagnostic Testing Diagnostic Centers and Clinics , by Region USD Million (2025-2030)
  • Table 173. Immunoprotein Diagnostic Testing Research Institutes , by Region USD Million (2025-2030)
  • Table 174. Immunoprotein Diagnostic Testing Others , by Region USD Million (2025-2030)
  • Table 175. South America Immunoprotein Diagnostic Testing, by Country USD Million (2025-2030)
  • Table 176. South America Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 177. South America Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 178. South America Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 179. South America Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 180. Brazil Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 181. Brazil Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 182. Brazil Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 183. Brazil Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 184. Argentina Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 185. Argentina Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 186. Argentina Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 187. Argentina Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 188. Rest of South America Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 189. Rest of South America Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 190. Rest of South America Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 191. Rest of South America Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 192. Asia Pacific Immunoprotein Diagnostic Testing, by Country USD Million (2025-2030)
  • Table 193. Asia Pacific Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 194. Asia Pacific Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 195. Asia Pacific Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 196. Asia Pacific Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 197. China Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 198. China Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 199. China Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 200. China Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 201. Japan Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 202. Japan Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 203. Japan Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 204. Japan Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 205. India Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 206. India Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 207. India Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 208. India Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 209. South Korea Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 210. South Korea Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 211. South Korea Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 212. South Korea Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 213. Taiwan Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 214. Taiwan Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 215. Taiwan Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 216. Taiwan Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 217. Australia Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 218. Australia Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 219. Australia Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 220. Australia Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 221. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 222. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 223. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 224. Rest of Asia-Pacific Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 225. Europe Immunoprotein Diagnostic Testing, by Country USD Million (2025-2030)
  • Table 226. Europe Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 227. Europe Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 228. Europe Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 229. Europe Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 230. Germany Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 231. Germany Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 232. Germany Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 233. Germany Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 234. France Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 235. France Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 236. France Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 237. France Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 238. Italy Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 239. Italy Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 240. Italy Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 241. Italy Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 242. United Kingdom Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 243. United Kingdom Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 244. United Kingdom Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 245. United Kingdom Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 246. Netherlands Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 247. Netherlands Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 248. Netherlands Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 249. Netherlands Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 250. Rest of Europe Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 251. Rest of Europe Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 252. Rest of Europe Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 253. Rest of Europe Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 254. MEA Immunoprotein Diagnostic Testing, by Country USD Million (2025-2030)
  • Table 255. MEA Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 256. MEA Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 257. MEA Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 258. MEA Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 259. Middle East Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 260. Middle East Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 261. Middle East Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 262. Middle East Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 263. Africa Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 264. Africa Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 265. Africa Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 266. Africa Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 267. North America Immunoprotein Diagnostic Testing, by Country USD Million (2025-2030)
  • Table 268. North America Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 269. North America Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 270. North America Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 271. North America Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 272. United States Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 273. United States Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 274. United States Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 275. United States Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 276. Canada Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 277. Canada Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 278. Canada Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 279. Canada Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 280. Mexico Immunoprotein Diagnostic Testing, by Type USD Million (2025-2030)
  • Table 281. Mexico Immunoprotein Diagnostic Testing, by Application USD Million (2025-2030)
  • Table 282. Mexico Immunoprotein Diagnostic Testing, by Technology USD Million (2025-2030)
  • Table 283. Mexico Immunoprotein Diagnostic Testing, by End User USD Million (2025-2030)
  • Table 284. Research Programs/Design for This Report
  • Table 285. Key Data Information from Secondary Sources
  • Table 286. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Immunoprotein Diagnostic Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Immunoprotein Diagnostic Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Immunoprotein Diagnostic Testing: by Technology USD Million (2018-2023)
  • Figure 7. Global Immunoprotein Diagnostic Testing: by End User USD Million (2018-2023)
  • Figure 8. South America Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 9. Asia Pacific Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 10. Europe Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 11. MEA Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 12. North America Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 13. Global Immunoprotein Diagnostic Testing share by Players 2023 (%)
  • Figure 14. Global Immunoprotein Diagnostic Testing share by Players (Top 3) 2023(%)
  • Figure 15. Global Immunoprotein Diagnostic Testing share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 19. Abcam PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Abcam PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Rad Laboratories (United States) Revenue: by Geography 2023
  • Figure 23. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Danaher Corporation (United States) Revenue: by Geography 2023
  • Figure 25. Diasorin (Italy) Revenue, Net Income and Gross profit
  • Figure 26. Diasorin (Italy) Revenue: by Geography 2023
  • Figure 27. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 29. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 30. Beckman Coulter (United States) Revenue: by Geography 2023
  • Figure 31. F. Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 33. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Siemens Healthineers (Germany) Revenue: by Geography 2023
  • Figure 35. Global Immunoprotein Diagnostic Testing: by Type USD Million (2025-2030)
  • Figure 36. Global Immunoprotein Diagnostic Testing: by Application USD Million (2025-2030)
  • Figure 37. Global Immunoprotein Diagnostic Testing: by Technology USD Million (2025-2030)
  • Figure 38. Global Immunoprotein Diagnostic Testing: by End User USD Million (2025-2030)
  • Figure 39. South America Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 40. Asia Pacific Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 41. Europe Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 42. MEA Immunoprotein Diagnostic Testing Share (%), by Country
  • Figure 43. North America Immunoprotein Diagnostic Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Abcam PLC (United Kingdom)
  • Bio-Rad Laboratories (United States)
  • Danaher Corporation (United States)
  • Diasorin (Italy)
  • Roche Diagnostics (Switzerland)
  • Beckman Coulter (United States)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Siemens Healthineers (Germany)
Additional players considered in the study are as follows:
A. Menarini Diagnostics (Italy) , Affymetrix (United States) , Agilent Technologies (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 250 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Immunoprotein Diagnostic Testing Market Quantitative research analysis
Global Immunoprotein Diagnostic Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Immunoprotein Diagnostic Testing market are Abbott Laboratories (United States), Abcam PLC (United Kingdom), Bio-Rad Laboratories (United States), Danaher Corporation (United States), Diasorin (Italy), Roche Diagnostics (Switzerland), Beckman Coulter (United States), F. Hoffman-La Roche Ltd. (Switzerland) and Siemens Healthineers (Germany), to name a few.
"Technological Advancements in Immunodiagnostic Instruments Introduction of Novel Automated Systems" is seen as one of major influencing trends for Immunoprotein Diagnostic Testing Market during projected period 2023-2030.
C-reactive Protein Diagnostic Test segment in Global market to hold robust market share owing to "Increase in Incidence & Prevalence of Infectious and Chronic Diseases ".

Know More About Global Immunoprotein Diagnostic Testing Market Report?

Have a Query? Click Here

Other Related Reports

Next Generation Cancer Diagnostic Comprehensive Study by Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), Function (Therapeutic Monitoring...
$ 3750
Wavefront LASIK Comprehensive Study by Type (Normal Wavefront, Aberrated Wavefront), Application (Eye Clinic, Hospital, Others), Technology (Wavefront-guided LASIK, Wavefront-optimized LASIK, Topogra...
$ 3450
Polymerase Chain Reaction Technologies Comprehensive Study by Type (Real-time PCR, Traditional PCR, Digital PCR), Application (Genetic Fingerprinting, Identification of Infectious Agents, Detection o...
$ 3750
Connected Patient Care Comprehensive Study by Type (M-Health Services, M-Health Devices, E-Prescription), Application (Monitoring, Diagnosis and Treatment, Education and Awareness, Healthcare Managem...
$ 3750
Artificial Intelligence In Diagnostic Comprehensive Study by Technology (Machine Learning, Natural Language Processing, Context-Aware Computing), Diagnosis (Cardiology,, Oncology,, Pathology,, Radiol...
$ 3750
Amniotic Products Comprehensive Study by Type (Amniotic Membranes (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Amniotic Suspensions), Application (Wound Care, Orthopedics, Ophth...
$ 3450